PANOPTICA
Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatme... nts for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
PANOPTICA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2009-01-01
Address:
Mount Arlington, New Jersey, United States
Country:
United States
Website Url:
http://www.panopticapharma.com
Total Employee:
101+
Status:
Active
Contact:
908-766-2202
Email Addresses:
[email protected]
Total Funding:
109.88 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome Wordpress Plugins
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
SV Health Investors
SV Health Investors investment in Series B - PanOptica
Third Rock Ventures
Third Rock Ventures investment in Series B - PanOptica
Third Rock Ventures
Third Rock Ventures investment in Series B - PanOptica
Novo Ventures
Novo Ventures investment in Series B - PanOptica
SV Health Investors
SV Health Investors investment in Series B - PanOptica
SV Health Investors
SV Health Investors investment in Series B - PanOptica
Dan Burgess
Dan Burgess investment in Series B - PanOptica
Novo Ventures
Novo Ventures investment in Series B - PanOptica
Third Rock Ventures
Third Rock Ventures investment in Series B - PanOptica
Astellas Venture Management
Astellas Venture Management investment in Series A - PanOptica
Official Site Inspections
http://www.panopticapharma.com Semrush global rank: 3.77 M Semrush visits lastest month: 3.58 K
- Host name: 178.212.196.104.bc.googleusercontent.com
- IP address: 104.196.212.178
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "PanOptica"
PanOptica - Crunchbase Company Profile & Funding
Organization. PanOptica . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. PanOptica is a biopharma company developing ophthalmic therapeutics for the treatment of …See details»
PanOptica Company Profile 2025: Valuation, Funding & Investors
PanOptica General Information Description. Developer of a topical eye drop designed to treat ophthalmic diseases. The company is developing an eye drop that helps in the effective …See details»
PanOptica, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
5 days ago panopticapharma.com. Holding Company | 2009 | New Jersey, United States | 100-250 | panopticapharma.com. Last update 31 Dec 2024. Overview. Pipeline. Deal. ... held …See details»
PanOptica - Org Chart, Teams, Culture & Jobs - The Org
View PanOptica's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
PanOptica - VentureRadar
PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock... ... Find out more ...See details»
PanOptica - Overview, News & Similar companies | ZoomInfo.com
Jun 17, 2021 Who is PanOptica. PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock Vent …See details»
PanOptica, Inc. Raises $30 Million in Series A Financing and
Jan 4, 2011 “As a company-building investment firm, we are pleased to support an organization that has such extensive and complementary experience in ophthalmology, bringing together …See details»
PanOptica Doses First Patient with New Formulation of PAN …
May 17, 2018 PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock Ventures, and SV Health …See details»
PanOptica | Company | Mindmaps
Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life.See details»
Panoptica, Inc Company Profile | Mount Arlington, NJ
Find company research, competitor information, contact details & financial data for Panoptica, Inc of Mount Arlington, NJ. Get the latest business insights from Dun & Bradstreet.See details»
PanOptica Announces Licensing Agreement with Zhaoke …
Jun 16, 2021 www.panopticapharma.com. About Zhaoke Ophthalmology Limited . Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to the research, …See details»
PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at
Www.panopticapharma.com. About PAN-90806 PAN-90806 is a potent and selective inhibitor of VEGF receptor signaling. VEGF is a protein that plays a critical role in angiogenesis (the …See details»
PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of …
Oct 9, 2019 PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock Ventures and SV Health …See details»
PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of
Oct 10, 2019 MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)-- PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today …See details»
PanOptica, Inc. Secures $11 Million To Advance Clinical ... - BioSpace
Oct 6, 2017 BERNARDSVILLE, N.J.--(BUSINESS WIRE)--PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today …See details»
PanOptica Announces Licensing Agreement with Zhaoke …
Jun 17, 2021 For more information, please visit www.panopticapharma.com. About Zhaoke Ophthalmology Limited. Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical …See details»
PanOptica_Series_B_Release_Oct-06-2017_en
Oct 6, 2017 more information, please visit www.panopticapharma.com. ### Contact: SmithSolve LLC on behalf of PanOptica Alex Van Rees, 973-442-1555 ext. 111 …See details»
PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at …
Oct 7, 2019 A copy of the presentation will be made available on the PanOptica website at www.panopticapharma.com. About PAN-90806 PAN-90806 is a potent and selective inhibitor …See details»
PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of …
Oct 10, 2019 Contacts. SmithSolve LLC on behalf of PanOptica Alex Van Rees, 973-442-1555 ext. 111 [email protected]See details»
PanOptica Reports Progress with PAN-90806, a Topical Anti- VEGF …
Nov 13, 2015 For more information, please visit www.panopticapharma.com. ### Contact: SmithSolve LLC on behalf of PanOptica Joe Pohl, 973-442-1555 ext. 113 …See details»